ArticlePloS one2017

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Svenja Nölting et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.